GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.
At the beginning of August, GPC Biotech provided an update on the development of 1D09C3. The company reported a number of significant achievements for this program, including: 1) consistent in vivo efficacy results in various lymphoid tumor animal models; 2) production of sufficient quantities of GMP-quality material for Phase 1/2 clinical trials; and 3) identification of an appropriate administration schedule.
GPC Biotech is developing a fully human anti-MHC class II monoclonal antibody, 1D09C3. This antibody binds to certain cell surface receptors, the so-called MHC (major histocompatibility complex) class II molecules, killing activated, proliferating MHC class II positive tumor cells, including B-cell- and T-cell-lymphomas and others. Normal, resting cells are not similarly killed. The antibody has been shown to induce programmed cell death. Cell death occurs rapidly via a novel mechanism-of-action that does not require a fully functioning immune system. Since most patients with these types of tumors are immunocompromised as a result of prior chemotherapy or the disease itself, this is potentially a significant advantage over most antibodies targeting B-cell lymphomas. This antibody was isolated by MorphoSys AG from its HuCAL(R) library of fully human antibodies and has a very high binding affinity to its MHC class II target.
GPC Biotech AG is a biotechnology company dedicated to discovering and developing new anticancer drugs through innovative discovery technologies and development approaches. The company's lead product candidate - satraplatin - has successfully completed Phase II clinical trials and is expected to enter a Phase III registrational study during 2003. The company is leveraging its drug discovery technologies in novel ways to elucidate the mechanisms-of- action of drug candidates and to support the growth of its drug pipeline. The company has formed successful collaborations with a number of pharmaceutical firms, including ALTANA Pharma of ALTANA AG (FSE: ALT; NYSE: AAA), Aventis Pharma (PAVE.PSE), Bayer AG (FSE: BAY; NYSE: BAY), Boehringer Ingelheim International GmbH, Eli Lilly and company (NYSE:LLY) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) . GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The company's wholly owned U.S. subsidiary has research sites in Waltham, Massachusetts and Princeton, New Jersey.
For more information, visit http://www.gpc-biotech.com or call 781/890-9007 ext. 267.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 1, 2003|
|Previous Article:||454 LIFE SCIENCES GETS GENOME LICENSE FROM PYROSEQUENCING.|
|Next Article:||CYTOCHROMA DISCOVERS NEW GENE CYP26C.|